PureTech Health plc (NASDAQ:PRTC) Short Interest Update

PureTech Health plc (NASDAQ:PRTC) saw a large decline in short interest in January. As of January 15th, there was short interest totalling 24,600 shares, a decline of 31.5% from the December 31st total of 35,900 shares. Based on an average daily volume of 4,600 shares, the short-interest ratio is currently 5.3 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in PureTech Health stock. Birch Hill Investment Advisors LLC purchased a new stake in shares of PureTech Health plc (NASDAQ:PRTC) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 302,000 shares of the company’s stock, valued at approximately $5,575,000. Birch Hill Investment Advisors LLC owned 1.26% of PureTech Health at the end of the most recent quarter. Hedge funds and other institutional investors own 0.04% of the company’s stock.

PureTech Health Stock Performance

Shares of NASDAQ:PRTC traded up $0.54 on Friday, reaching $19.10. 2,082 shares of the company were exchanged, compared to its average volume of 3,336. The company has a 50-day moving average of $19.86 and a 200-day moving average of $20.77. PureTech Health has a 1-year low of $17.00 and a 1-year high of $34.00.

PureTech Health Company Profile

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.